. Author manuscript; available in PMC: 2016 Jun 3.

Published in final edited form as: Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jan 17;59:40–48. doi: 10.1016/j.pnpbp.2015.01.009

Table 2.

Incidence of adverse events reported in >2 subjects by preferred term, period & treatment group.

Preferred term	Placebo-only		Placebo–Cocaine		Treatment–Cocaine

	Nepicastat (n = 15)	Placebo (n = 5)	Nepicastat (n = 15)	Placebo (n = 5)	Nepicastat (n = 14)^a	Placebo (n = 4)^b
Insomnia	2 (13)	0 (0)	1 (6)	1 (20)	4 (29)	1 (25)
Vessel puncture site pain	0 (0)	0 (0)	2 (13)	1 (20)	4 (29)	0 (0)
Dyspepsia	0 (0)	0 (0)	1 (6)	0 (0)	2 (14)	1 (25)
Gastroesophageal reflux disease	1 (6)	0 (0)	0 (0)	0 (0)	3 (21)	0 (0)
Headache	0 (0)	1 (20)	1 (6)	0 (0)	2 (14)	1 (25)
Neck pain	0 (0)	0 (0)	0 (0)	0 (0)	2 (14)	1 (25)
Arthralgia	0 (0)	0 (0)	1 (6)	0 (0)	2 (14)	0 (0)
Dizziness	0 (0)	0 (0)	0 (0)	1 (20)	0 (0)	2 (50)
Back pain	1 (6)	1 (20)	0 (0)	0 (0)	0 (0)	1 (25)
Myalgia	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (50)
Nausea	1 (6)	0 (0)	0 (0)	0 (0)	1 (7)	1 (25)
Depressed mood	1 (6)	0 (0)	0 (0)	0 (0)	1 (7)	1 (25)
Abnormal dreams	2 (13)	0 (0)	0 (0)	1 (20)	0 (0)	1 (25)
Vessel puncture site hematoma	0 (0)	0 (0)	2 (13)	0 (0)	0 (0)	0 (0)

Values reflect the number (%) of subjects.

Subject 117 completed the “placebo only” and “placebo–cocaine” periods only.

Subject 112 completed the “placebo-only” period and a partial “placebo–cocaine” period.